XML 43 R26.htm IDEA: XBRL DOCUMENT v3.25.4

Common Stock, Stock Options, Restricted Stock Awards, and Warrants (Tables)

12 Months Ended

Sep. 30, 2025

Common Stock, Stock Options, Restricted Stock Awards, and Warrants [Abstract]

Schedule of Assumptions were used in determining the Fair Value of Stock Option

The following assumptions were used in determining the fair value of stock option grants for the years ended September 30, 2025 and 2024:

		2025		2024
Risk-free interest rate		4.17 – 4.31%		4.62 – 4.66%
Expected dividend yield		0.00%		0.00%
Expected term		5.50 – 10 years		5.50 – 10 years
Expected volatility		85%		85 – 86%

The following assumptions were used in determining the fair value of the Citius Oncology stock option grants for the year ended September 30, 2025 and 2024:

		2025		2024
Risk-free interest rate		4.08-4.18%		4.66%
Expected dividend yield		0.00		0.00%
Expected term		5.50-6.50 years		6.50 years
Expected volatility		85%		87%

Schedule of Option Activity Under Our Stock Option Plans

A summary of option activity under our plans (excluding the NoveCite and Citius Oncology Stock Plans) is presented below:

		Option Shares				Weighted- Average Exercise Price				Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at September 30, 2024			656,084			$	36.41			7.26 years		$	0.00
Granted			185,000			$	9.50
Exercised			—
Forfeited or expired			(1,574	)		$	242.80
Outstanding at September 30, 2025			839,510			$	30.09			6.90 years		$	0.00
Exercisable at September 30, 2025			512,509			$	39.70			5.88 years		$	0.00

 A summary of option activity under the Citius Oncology plan is presented below:

		Shares				Weighted- Average Exercise Price				Weighted- Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at September 30, 2024			12,750,000			$	2.15			8.78 years		$	—
Granted			5,750,000				1.07
Forfeited			(400,000	)
Outstanding at September 30, 2025			18,100,000			$	1.83			8.21 years		$	5,386,000
Exercisable at September 30, 2025			9,781,250			$	2.02			7.94 years		$	1,136,500

Schedule of Exercise of Outstanding Warrants

The following table summarizes the warrants outstanding at September 30, 2025:

		Exercise price				Number				Expiration Dates
August 2018 Offering Investors			28.75				156,863			August 14, 2026
August 2018 Offering Agent			39.84				7,576			August 8, 2026
September 2019 Offering Investors			19.25				111,732			September 27, 2026
September 2019 Offering Underwriter			27.97				7,774			September 27, 2026
May 2020 Offering Investors			25.00				66,824			November 18, 2025
January 2021 Offering Investors			30.78				123,648			July 27, 2026
January 2021 Offering Agent			40.44				14,065			July 27, 2026
February 2021 Offering Investors			42.50				823,211			February 19, 2026
February 2021 Offering Agent			47.03				100,256			February 19, 2026
May 2023 Offering Investors			37.50				500,000			May 8, 2028
May 2023 Offering Agent			37.50				35,000			May 3, 2028
April 2024 Offering Investors			18.75				857,143			October 30, 2029
April 2024 Offering Agent			21.875				60,000			April 25, 2029
November 2024 Offering Investors			6.25				480,000			November 18, 2029
November 2024 Offering Agent			7.8125				33,600			November 15, 2029
January 2025 Offering Investors			3.91				743,496			January 8, 2030
January 2025 Offering Agent			5.0438				52,045			January 7, 2030
April 2025 Offering Agent			1.4375				121,739			April 1, 2030
June 2025 Offering Investor			1.00				9,840,000			June 11, 2027
June 2025 Offering Agent			1.525				344,400			June 11, 2027
							14,479,372

The following table summarizes the warrants outstanding at September 30, 2025:

		Exercise price				Number				Expiration Dates
July 2025 Offering Investors		$	1.32				6,818,182			July 17, 2030
July 2025 Offering Agent			1.65				272,727			July 17, 2030
July 2025 Prior Offering Agent			1.65				477,273			July 17, 2030
September 2025 Offering Investors			1.84				5,142,858			March 10, 2031
September 2025 Offering Agent			1.92				205,714			March 10, 2031
September 2025 Prior Offering Agent			2.1875				360,000			March 10, 2031
							13,276,754

Schedule of Common Stock Reserved for Future Issuances

A summary of common stock reserved for future issuances by Citius Pharma excluding our subsidiaries as of September 30, 2025 is as follows:

Stock plan options outstanding			839,510
Stock plan shares available for future grants			118,000
Warrants outstanding			14,479,372
Total			15,436,882

A summary of common stock reserved for future issuances by Citius Oncology as of September 30, 2025 is as follows:

Stock plan options outstanding			18,100,000
Restricted stock awards			11,600,000
Stock plan shares available for future grants			300,000
Warrants outstanding			13,276,754
Total			43,276,754

X

- Definition

Tabular disclosure of the change in common stock outstanding.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (f)(2)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

+ Details

Name:	us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_StockholdersEquityNoteAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration